CalciMedica, Inc.
CALCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 20, 2024 | Oppenheimer | Leland Gershall | $14.00(+157%) | $5.45 | StreetInsider |
| Nov 22, 2022 | Raymond James | Christopher Raymond | $2.00(-99%) | $146.90 | TheFly |
| May 18, 2022 | Piper Sandler | Christopher Raymond | $2.00(-99%) | $171.81 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | Mar 5, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jan 29, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2024 |
| Oppenheimer | maintain | Outperform | Jul 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| Oppenheimer | maintain | Outperform | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 13, 2024 |
| Oppenheimer | maintain | Outperform | Nov 13, 2023 |
| EF Hutton | maintain | Buy | Jul 7, 2023 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-1.27| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-2.25 | $-1.43 | — | — |
| May 13, 2026 | $-1.50 | $-1.40 | — | — |
| Mar 26, 2026 | $-3.40 | $-2.75 | — | $33.3M |
| Nov 12, 2025 | $-2.60 | $-2.06 | — | — |
| Aug 11, 2025 | $-2.00 | $-2.00 | — | — |
| May 14, 2025 | $-1.80 | $-2.15 | — | — |
| Mar 27, 2025 | $-0.34 | $-0.48 | — | — |
| Nov 13, 2024 | $-2.50 | $-2.50 | — | — |
News
LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 9:30 a.m.
Shares of CalciMedica Inc. (NASDAQ: CALC - Get Free Report) have been assigned a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1x1 investor meetings at the H.C.
LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-5, effective at 5:00 p.m.